Results 61 to 70 of about 9,061 (176)

Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/HER2‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Purpose The optimal chemotherapy strategy after progression on cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) metastatic breast cancer remains a matter of controversy.
Lara Laini, Deborah Cosentini, Marta Laganà, Salvatore Grisanti, Giulia Scartabellati, Gianluca Fogazzi, Salvatore Strazzeri, Vito Amoroso, Greta Schivardi, Rebecca Pedersini, Alfredo Berruti, Antonella Turla   +11 more
wiley   +1 more source

Mapping Mutations and Signaling Network Interactions to Guide Precision Therapy in Gallbladder Cancer

Cancer Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical location, resulting in diagnosis at ...
Nisha Manav, Akanksha Kashyap, Lakshay Malhotra, Chethan Rajegowda, Chandra Prakash Prasad   +4 more
wiley   +1 more source

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

MedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao, Wenchao Xu, Yibo Wang, Haoran Huang, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +7 more
wiley   +1 more source

Abemaciclib Persistence in Patients with HR+, HER2−, Node-Positive Early Breast Cancer: a Real-World Analysis

Oncology and Therapy
Introduction Patients with node-positive, high-risk, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (EBC) can be treated with 2 years of abemaciclib plus endocrine therapy (ET) to improve ...
Kathryn Hudson, Wambui Gathirua-Mwangi, Lindsay A. Williams, Zhanglin Lin Cui, Madeline Richey, Brenda Grimes, Jingru Wang, Astra M. Liepa, Erich Brechtelsbauer, Raisa Volodarsky, Katheryn Moreira, Hatem Soliman   +11 more
doaj   +1 more source

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels

Cancer Management and Research, 2022
Norikazu Masuda,1 Yucherng Chen,2 Tsutomu Kawaguchi,3 Koji Dozono,4 Masakazu Toi5 1Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; 2Safety Science, Quality and Patient Safety, Eli Lilly Japan K.K.,
Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M   +4 more
doaj  

Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR‐Positive, HER2‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Endocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2− breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy‐CDK4/6 inhibitors with chemotherapy alone in HR+/HER2− breast ...
Xiaopei Dong, Fan Li, Yang Yuan, Hua Song, Yingzhe Wang, Yi Hao, Yinping Dong, Tao Wang, Li Bian, Shaohua Zhang, Jianbin Li   +10 more
wiley   +1 more source

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer

, 2018
Silvia Paola Corona,1 Daniele Generali2 1Radiation Oncology Department, Peter MacCallum Cancer Centre, Bentleigh East, VIC, Australia; 2Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy Abstract: Although early ...
Generali D, Corona SP
core  

Imaging Pitfalls in Evaluating Liver Metastases in Breast Cancer With Autosomal Dominant Polycystic Kidney Disease‐Associated Polycystic Liver: A Case Report

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT Extensive hepatic cysts in ADPKD, together with a diffuse infiltrative liver metastatic pattern, can lead to radiological underestimation of hepatic tumor burden on conventional whole‐body imaging. Persistent biomarker–imaging discordance should prompt reassessment of disease progression at known sites and involvement of other organs, with ...
Saho Aso, Ritsuko Sasaki, Haruna Kawano, Hiroko Onagi, Harumi Saeki, Misato Okazaki, Kotaro Ijima, Goro Kutomi   +7 more
wiley   +1 more source

Abstract OT2-01-08: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2- metastatic breast cancer

, 2017
Background: Abemaciclib, an oral drug administered twice daily on a continuous schedule, is a specific inhibitor of both CDK4 and CDK6.
E Hamilton, EL Johnston, V Diéras, M Martín, T Forrester   +4 more
core   +1 more source

Volumetric Microsampling for Patient‐Centric Therapeutic Drug Monitoring in Clinical Pharmacology: A Scoping Review

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Accurate drug concentration measurement is essential for precision pharmacotherapy, but conventional therapeutic drug monitoring (TDM) requires venous sampling, increasing patient burden, and potentially limiting participation in TDM and model‐informed precision dosing (MIPD).
Hari Prabhath Tummala, Abbie D. Leino, Nathaniel J. Rhodes, Kevin J. Downes, Marc H. Scheetz, Manjunath P. Pai   +5 more
wiley   +1 more source